Docket No. <u>2976-4032</u> 6/16/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ros

Rosenblum et al.

Group Art Unit:

RECEIVED

Serial No.:

09/594,996

Berch, M.

1624

JUN 1-4 2001

Filed:

June 15, 2000

erch, M.

TECH CENTER 1600/2900

For:

HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL

Examiner:

AS HYPOCHOLESTEROLEMIC AGENTS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching. 1. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed: For each of the following items listed on the enclosed copy of Form PTO-1449 that is 2. not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application. 3. Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed ____ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement X since it is being filed in compliance with: 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or

			37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
			37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
		\boxtimes	37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.	
6.		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Stateme it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specific paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):	
			A check in the amount of \$180.00 is enclosed in payment of the fee.
			Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
it is being filed in compliance with 37 C.F.R. §1.9		it is be	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since sing filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final or a notice of allowance, whichever comes first, but before payment of the issue id is accompanied by:
			ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and
			e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 elow.
8.			is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since sing filed in compliance with:
		a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
		b. 🗌	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).

	c. The fees due under 37 C.F.R. sparagraph 11 below.	§§1.17(h) and 1.17(p) are paid as set forth in	
9.	Statement was first cited in a commun	rmation contained in this Information Disclosure ication from a foreign patent office in a ore than three months prior to the filing of this	
	I hereby certify that no item of information in the Information Disclosure Stafiled herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable was known to any individual designated in §1.56(c) more than three months the filing of this Information Disclosure Statement.		
10.	This document is accompanied by a Search Report Communication which cited in a corresponding PCT or Foreign counterpart application		
11.	A check in the amount of \$ is er C.F.R. §§1.17(h) and 1.17(p).	nclosed in payment of the fees due under 37	
	Charge the fees due under 37 C.F.R. § 13-4500, Order No A DUPLI ATTACHED.	§1.17(h) and 1.17(p) to Deposit Account No. CATE COPY OF THIS SHEET IS	
	required for this Information Disclosur	ed to charge any additional fees which may be re Statement, or credit any overpayment to No. 2976-4032. A DUPLICATE COPY OF	
		Respectfully submitted,	
Dated: Ju	nne 13, 2001	By: Michael S. Marcus	
		Reg. No. 31,727	

Correspondence Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone (212) 751-6849 Facsimile